Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.44 USD | +1.82% | +5.21% | +68.10% |
May. 10 | Wedbush Raises Edgewise Therapeutics' PT to $31 From $26, Keeps Outperform Rating | MT |
May. 09 | Edgewise Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+68.10% | 1.69B | |
+42.31% | 50.93B | |
-0.60% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+13.42% | 26.02B | |
-22.04% | 18.9B | |
+7.44% | 13.21B | |
+24.04% | 12.17B | |
+30.19% | 12.16B |
- Stock Market
- Equities
- EWTX Stock
- News Edgewise Therapeutics, Inc.
- Edgewise Therapeutics Says First Patient Dosed in Phase 2 Hypertrophic Cardiomyopathy Trial